U.S. Online Retail and Ecommerce Stock News

For investors considering whether Restaurant Brands International at around US$73.76 represents fair value or a potential opportunity, this article focuses on what the current share price implies. The stock has declined 1.7% over the last 7 days, with returns of 2.9% over 30 days, 8.8% year to date, 14.8% over 1 year, 20.9% over 3 years, and 34.0% over 5 years. These figures can influence how investors think about both potential upside and risk. Recent news coverage has largely focused on...

In late March 2026, The Trade Desk disclosed that a board resignation left its audit and compensation committees temporarily out of compliance with Nasdaq’s independence rules, while also moving to appoint experienced finance executive Drew Vollero as a new director. This governance reshuffle highlights how board composition and committee structure can matter for investors assessing oversight, risk controls, and long-term value creation. Next, we’ll examine how the audit committee shortfall...

In March 2026, Zillow Group launched Zillow AI mode and Zillow Preview, expanded these tools through partnerships with major brokerages such as HomeServices of America and William Raveis, reaffirmed first-quarter 2026 revenue guidance of US$700 million to US$710 million and full-year 2026 targets, and saw Compass move to dismiss its lawsuit after Zillow ended its prior “Zillow Ban” policy. Together, these AI-driven product launches, listing-transparency initiatives and policy changes suggest...

Hims & Hers Health (NYSE:HIMS) has launched access to Novo Nordisk FDA-approved GLP-1 medications for eligible patients. The offering includes a range of GLP-1 options, including the only pill currently approved for weight loss. The company also introduced a new weight loss membership that combines medication access with broader support services. Hims & Hers Health focuses on telehealth and subscription based care, and GLP-1 weight loss treatments have become a key area of interest for both...

Recent performance snapshot Genworth Financial (GNW) has drawn attention after recent trading, with the share price at $8.05 and a market cap of about $3.1 billion. This has prompted investors to reassess its returns and fundamentals. See our latest analysis for Genworth Financial. Recent trading has been softer, with a 30 day share price return of a 4.62% decline and a 90 day share price return of an 11.54% decline. However, longer term total shareholder returns of 13.54% over one year and...

Apple (NasdaqGS:AAPL) has been fined after self reporting a breach of Russian sanctions tied to payments for a streaming app owned by a sanctioned entity. The company has committed to strengthen its internal controls and compliance protocols following the incident. The case highlights how large global platforms can be exposed to complex sanctions frameworks across multiple jurisdictions. Apple remains primarily known for its hardware ecosystem, software services, and expanding subscription...

Amentum Holdings (NYSE:AMTM) secures a $112 million contract for nuclear decommissioning and waste management. The multi country agreement covers projects across several European markets. The contract focuses on dismantling nuclear facilities and managing radioactive waste. The award highlights Amentum Holdings' role in specialist nuclear services, a segment where safety, regulation, and technical expertise are central. For investors following NYSE:AMTM, this type of long duration, complex...

Is Vertex Pharmaceuticals stock offering a discount after recent weakness? Vertex Pharmaceuticals (VRTX) has seen its share price under pressure over the past month, raising questions for investors about how the current valuation lines up with the company’s revenue, earnings profile, and long term returns. See our latest analysis for Vertex Pharmaceuticals. At a recent share price of US$443.16, Vertex has seen a 10.8% 1 month share price decline and a 1 year total shareholder return decline...

In late March 2026, Guardant Health reported that real-world evidence from its InfinityAI and Guardant360 platforms helped support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating certain advanced or recurrent HER2‑positive solid tumors when standard therapies fail. This use of Guardant’s clinicogenomic data as supplemental evidence in a national regulatory decision highlights how its AI‑driven real‑world datasets are becoming directly embedded in oncology drug approvals across...

Why Target (TGT) is Back on Investors’ Radar Target (TGT) is drawing investor attention after recent share price moves, with returns over the past month and past 3 months standing out against its mixed multi year track record. See our latest analysis for Target. The recent momentum is clear, with a 7 day share price return of 3.35%, a 90 day share price return of 21.91%, and a 1 year total shareholder return of 19.03% standing against weaker three and five year total shareholder returns. If...

Wondering if Cactus at around US$46.70 is priced attractively or already reflects its strengths? This article walks through the key signals that matter for valuation-focused investors. The stock has seen a 2.2% decline over the last week and a 13.5% decline over the last month, while still showing returns of 3.2% over 1 year, 11.4% over 3 years and 58.7% over 5 years. These moves sit against a backdrop where investors are watching sector-wide sentiment and company-specific developments...

If you are wondering whether Warner Bros. Discovery at around US$27.09 is still offering value after a strong run, this breakdown will help you weigh what the current price really reflects. The stock is down 1.1% over the past week, 3.8% over the past month and 5.0% year to date, but it has returned 152.5% over the last year and 82.9% over three years, compared with a 34.9% decline over five years. Recent headlines have focused on Warner Bros. Discovery's ongoing efforts to integrate its...

Verizon Communications (VZ) is back on investors’ radar as its share price reflects mixed recent returns, including a small 1 day decline alongside positive month and past 3 months performance. See our latest analysis for Verizon Communications. Despite a small 7 day share price pullback, Verizon’s current share price of $50.30 comes after a 90 day share price return of 23.59% and a 1 year total shareholder return of 18.48%, suggesting momentum has been building over the medium term. If...

If you are wondering whether Walt Disney at around US$94.32 is a bargain or a value trap, you are not alone. That is exactly what this article will help you unpack. The stock has seen a 3.7% decline over the last 7 days, an 11.1% decline over 30 days, a 15.7% decline year to date, and a 3.4% decline over the past year. This naturally raises questions about potential opportunity or shifting risk perceptions. Recent headlines have focused on Walt Disney's content pipeline, theme park...

McEwen (NYSE:MUX) has put its Tartan Mine Project in Manitoba in focus after publishing an updated Mineral Resource Estimate that details over 600,000 combined indicated and inferred gold ounces and outlines further drilling plans. See our latest analysis for McEwen. Despite the positive Tartan update, McEwen’s recent share price performance has cooled, with a 1‑month share price return of a 33.5% decline after a largely flat 90‑day move. The 1‑year total shareholder return of 149.8% shows...

Firefly Aerospace (FLY) is back in focus after supporting Lockheed Martin and the U.S. Space Force on the VICTUS DIEM mission. The company completed rapid payload processing and emergency launch simulations on compressed timelines. See our latest analysis for Firefly Aerospace. The recent VICTUS DIEM exercises and updated 2026 revenue guidance have come alongside a 22.57% 30 day share price return, while the year to date share price return of a 0.59% decline suggests momentum is still forming...

Manchester United (NYSE:MANU) shares have recently attracted fresh attention after the club reported annual revenue of £655.401 million alongside a net loss of £9.064 million, prompting investors to reassess how the listed entity converts global brand strength into financial returns. See our latest analysis for Manchester United. At a share price of $16.43, Manchester United has seen a 1-year total shareholder return of 25.52% while the 3-year total shareholder return is negative 23.58%. This...

Fermi has yet to secure a cornerstone tenant for its flagship Project Matador campus, despite progressing permits that target 17 GW of power capacity. The company has made substantial capital commitments and lined up equipment financing, but no anchor customer contract has been confirmed. This gap between infrastructure build out and tenant sign on is raising questions about future revenue visibility and the private grid model. For investors watching NasdaqGS:FRMI, the lack of an anchor...

Commercial Metals increased its regular quarterly dividend for the 246th consecutive quarter. The latest dividend raise extends a multidecade record of uninterrupted quarterly increases. The move signals continued commitment to returning cash to shareholders. For investors watching NYSE:CMC, this dividend hike arrives with the stock trading around $60.09. The share price has seen a 31.8% gain over the past year and a 103.2% gain over the past five years, while the year-to-date return stands...

To figure out whether Tenable Holdings might still deserve a spot on your watchlist, it helps to separate emotion from price and look closely at what the current share level really implies about value. That question feels especially relevant now because the stock is trading at US$17.06, with returns of a 15.8% decline over 7 days, an 11.3% decline over 30 days, a 24.9% decline year to date, a 51.2% decline over 1 year, a 62.8% decline over 3 years, and a 54.0% decline over 5 years. Recent...

In March 2026, H.B. Fuller reported first-quarter 2026 results showing sales of US$770.84 million versus US$788.66 million a year earlier, with net income rising to US$21.05 million and basic and diluted EPS from continuing operations increasing to US$0.38 from US$0.24. Alongside this profitability improvement, the company raised its full-year 2026 net revenue guidance to mid-single-digit growth and signaled low-single-digit growth for the second quarter, indicating management’s increased...

If you are wondering whether PDD Holdings at around US$98.42 offers good value or just extra risk, you will want to see how the current price stacks up against its fundamentals. The stock has recently shown a 2.3% gain over the last 7 days, while returns stand at a 5.1% decline over 30 days, a 15.0% decline year to date, and a 16.8% decline over the past year, set against a 31.5% return over three years and a 31.1% decline over five years. Recent coverage has focused on PDD Holdings as a...

Ameris Bancorp (ABCB) has drawn fresh attention after a recent move in its share price, with the stock closing at US$76.53. Investors are weighing this level against its recent performance and fundamentals. See our latest analysis for Ameris Bancorp. The recent 0.84% 1-day share price return, putting Ameris Bancorp at US$76.53, sits against a modest 3.45% year-to-date share price return but a much stronger 34.41% 1-year total shareholder return, suggesting momentum has been building over a...

Teva Pharmaceutical Industries (NYSE:TEVA) received FDA approval for PONLIMSI, its denosumab biosimilar to Prolia. The company has also submitted regulatory applications for a biosimilar to Xolair in both the US and EU. These developments align with Teva's Pivot to Growth plan and expand its presence in the biosimilars segment. Teva enters this phase of its Pivot to Growth plan with its share price at $28.35 and a 1-year return of 84.5%. Over 3 years, the stock is up 210.9%, and over 5...